伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EXEL 伊克力西斯

休市中 01-03 16:00:00 EST

33.97

+0.03

+0.09%

盘后33.97

+0.000.00%

17:35 EST

最高34.12	最低33.79	成交量130.74万
今开33.79	昨收33.94	日振幅0.97%
总市值97.01亿	流通市值81.75亿	总股本2.86亿
成交额4,440万	换手率0.54%	流通股本2.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"伊克力西斯","latestPrice":33.97,"timestamp":1735938000000,"preClose":33.94,"halted":0,"volume":1307404,"hourTrading":{"tag":"盘后","latestPrice":33.97,"preClose":33.97,"latestTime":"17:35 EST","volume":107028,"amount":3635715.0827,"timestamp":1735943730629},"delay":0,"floatShares":240655698,"shares":285579020,"eps":1.54776,"marketStatus":"休市中","change":0.03,"latestTime":"01-03 16:00:00 EST","open":33.79,"high":34.12,"low":33.79,"amount":44397104.816456,"amplitude":0.009723,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.54776,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1736154000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":33.94,"preHourTrading":{"tag":"盘前","latestPrice":33.79,"preClose":33.94,"latestTime":"09:22 EST","volume":22,"amount":744.7300079999999,"timestamp":1735914166896},"postHourTrading":{"tag":"盘后","latestPrice":33.97,"preClose":33.97,"latestTime":"17:35 EST","volume":107028,"amount":3635715.0827,"timestamp":1735943730629},"volumeRatio":0.942633,"impliedVol":0.3468,"impliedVolPercentile":0.2143},"requestUrl":"/m/hq/s/EXEL/wiki","defaultTab":"wiki","newsList":[{"id":"2495548114","title":"美国研究综述-Arcutis Biotherapeutics、Artiva Biotherapeutics、Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2495548114","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495548114?lang=zh_cn&edition=full","pubTime":"2024-12-30 19:40","pubTimestamp":1735558829,"startTime":"0","endTime":"0","summary":"美国研究综述-Arcutis Biotherapeutics、Artiva Biotherapeutics、Nuvalent路透12月30日 - 华尔街证券分析师周一调整了对Arcutis Biotherapeutics、Artiva Biotherapeutics和Nuvalent等几家美国上市公司的评级和目标价。要点   * Arcutis Biotherapeutics ARQT.O：H.C. Wainwright给予买入评级 * Artiva Biotherapeutics ARTV.O：H.C. Wainwright 给予买入评级  * Nuvalent Inc NUVL.O：H.C. Wainwright 给予买入评级，目标价 110 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4T3NV0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0187121727.USD","LU0882574055.USD","LU0345769631.USD","LU2265009873.SGD","LU0345769128.USD","BK4588","BK4139","BK4551","LU2324357040.USD","LU0122379950.USD","LU0823416689.USD","IE0002141913.USD","LU2362540622.SGD","LU1023059063.AUD","LU0267386448.USD","BK4587","LU1989772923.USD","NUVL","BBAI","LU1804176565.USD","LU0950375773.USD","EXEL","LU2506952097.USD","LU2506951958.HKD","PODD","IE00BJT1NW94.SGD","BK4581","EBS","IE00B4R5TH58.HKD","LU1153585028.USD","LU0011850046.USD","MTVA","LU2087625088.SGD","LU2362541273.HKD","LU0353189680.USD","LU1791710582.SGD","BSX","BK4583","LU0048584097.USD","LU0823417737.USD","LU2491049909.HKD","LU1718418525.SGD","BK4539","ARTV","LU0238689110.USD","LU2491050154.USD","ARQT","LU2491050071.SGD","BK4082","LU1061106388.HKD"],"gpt_icon":1},{"id":"2493696796","title":"BUZZ-Brookline Capital Markets 给予 Exelixis \"买入 \"评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2493696796","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493696796?lang=zh_cn&edition=full","pubTime":"2024-12-24 02:01","pubTimestamp":1734976907,"startTime":"0","endTime":"0","summary":"BUZZ-Brookline Capital Markets 给予 Exelixis \"买入 \"评级12月23日 -  ** Brookline Capital Markets给予生物技术公司Exelixis EXEL.O\"买入 \"评级  ** 券商预计EXEL将开发其商业药物Cabometyx和Cometriq ** 称EXEL的产品总销售额将在2033年达到67亿美元 ** 券商将目标价定为40美元，较上一交易日收盘价上涨20.2%。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nL4S3NO102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2490889313","title":"2023 年，无依据的价格上涨将使美国药品支出增加 8.15 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490889313","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490889313?lang=zh_cn&edition=full","pubTime":"2024-12-12 21:00","pubTimestamp":1734008415,"startTime":"0","endTime":"0","summary":"2023 年，无依据的价格上涨将使美国药品支出增加 8.15 亿美元Sriparna  Roy路透12月12日 - 一个有影响力的药品定价监督机构周四表示，2023 年对美国医疗支出增长贡献最大的 10 种药品中，有 5 种药品的提价没有得到临床证据的支持，导致成本增加了 8.15 亿美元。报告称，该疗法的上市价格上涨了7.6%，使美国的支出增加了约1.9亿美元。根据美国定价研究公司的数据，去年，10 种高支出药品中有 8 种大幅提价，增加了 12.7 亿美元的成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nL4S3ND0XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1066051498.USD","LU0912757837.SGD","SG9999001176.USD","SG9999013999.USD","LU0965508806.USD","BK4588","LU1934455277.USD","JNJ","SG9999002224.SGD","LU1037948541.HKD","LU1941712348.USD","PFE","EXEL","LU0965509101.SGD","LU1057294990.SGD","IE00BSNM7G36.USD","LU1778281490.HKD","LU2089984988.USD","SG9999015341.SGD","GILD","LU0170899867.USD","LU0889566641.SGD","BK4533","LU0965509283.SGD","LU0456855351.SGD","SG9999014542.SGD","LU1941712264.USD","LU0070302665.USD","BK4592","BK4516","LU1732800096.USD","LU0320765489.SGD","LU2602419157.SGD","IE00BVYPNV92.GBP","SG9999014575.USD","LU1196500208.SGD","LU1291159041.SGD","LU0640476718.USD","IE00BGHQF631.EUR","LU0106261372.USD","LU1221951046.USD","MRK","LU0238689110.USD","LU1032466523.USD","LU1934455863.HKD","LU2087621335.USD","BK4550","LU2023250504.SGD","LU1061106388.HKD"],"gpt_icon":1},{"id":"2480864875","title":"伊克力西斯2024财年第三财季实现净利润1.18亿美元，同比增加11246.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480864875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480864875?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563257,"startTime":"0","endTime":"0","summary":"11月3日，伊克力西斯公布财报，公告显示公司2024财年第三财季净利润为1.18亿美元，同比增加11246.15%；其中营业收入为5.40亿美元，同比增加14.41%，每股基本收益为0.41美元。从资产负债表来看，伊克力西斯总负债6.85亿美元，其中短期债务0.00美元，资产负债比为4.33，流动比率为3.94。机构评级：截至2024年11月3日，当前有20家机构对伊克力西斯目标价做出预测，其中目标均价为32.35美元，其中最低目标价为23.00美元，最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000126ab98f4fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000126ab98f4fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"1163295106","title":"异动解读 | 伊克力西斯(EXEL)业绩超预期加利好预期 股价盘中大涨12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163295106","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163295106?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:40","pubTimestamp":1730295641,"startTime":"0","endTime":"0","summary":"伊克力西斯今日盘中股价大涨12.08%,报收30.72美元,引发市场广泛关注。公司刚刚公布的第三季度财报显示,营收达到5.39亿美元,超出市场预期4.9亿美元的水平。调整后每股收益为0.47美元,也高于预期的0.35美元。出色的业绩给投资者带来了积极信号,推动了股价在盘中交易中的大涨。分析人士表示,伊克力西斯业绩超预期及利好预期的释放,有望支撑其股价在短期内保持涨势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0},{"id":"2479783216","title":"伊克力西斯盘中异动 早盘股价大涨10.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479783216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479783216?lang=zh_cn&edition=full","pubTime":"2024-10-30 21:31","pubTimestamp":1730295084,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时31分，伊克力西斯股票出现波动，股价大幅拉升10.30%。截至发稿，该股报31.69美元/股，成交量22.6493万股，换手率0.08%，振幅2.58%。机构评级方面，在所有23家参与评级的机构中，61%的券商给予买入建议，30%的券商给予持有建议，9%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中，整体跌幅为0.30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021312495bd8dd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021312495bd8dd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":1},{"id":"2479759012","title":"伊克力西斯(EXEL)盘前升近7% 第三季度收入超预期并调升全年净产品收入和总收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2479759012","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479759012?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:52","pubTimestamp":1730281970,"startTime":"0","endTime":"0","summary":"金吾财讯 | 伊克力西斯(EXEL)盘前股价走高，暂升6.93%，报30.72美元。公司于第三季度录得总收入5.395亿美元，超预期。公司提高了2024 年全年净产品收入和总收入预期 。TD Cowen和JMP均维持公司买入评级及目标价34美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/NWUyOTcwN2U1MzQ2YjViNjMyZDcwZGM2MmQ0YzE5MjMxNzMwNDc5NDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NWUyOTcwN2U1MzQ2YjViNjMyZDcwZGM2MmQ0YzE5MjMxNzMwNDc5NDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281429","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"1195530354","title":"异动解读 | 业绩超预期且预期向好 伊克力西斯股价盘前大涨5.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195530354","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195530354?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:40","pubTimestamp":1730281214,"startTime":"0","endTime":"0","summary":"伊克力西斯(EXEL)公司周二盘前大涨5.81%,报收30.39美元,引发市场广泛关注。\n\n公司刚刚公布的第三季度财报显示,伊克力西斯季度营收达到5.39亿美元,超出市场预期4.9亿美元的水平。调整后每股收益达0.47美元,高于预期的0.35美元。公司的业绩表现优于预期,给投资者带来积极信号,推动了股价在盘前交易中的上涨。\n\n值得一提的是,公司还上调了2024年全年收入预测。尽管目前未透露调高的具体幅度,但这一举动反映出公司对业务未来发展的信心,从而进一步提振了市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0},{"id":"2479278798","title":"美股异动丨伊克力西斯盘前涨约6% Q3业绩超预期 上调收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2479278798","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479278798?lang=zh_cn&edition=full","pubTime":"2024-10-30 17:14","pubTimestamp":1730279640,"startTime":"0","endTime":"0","summary":"格隆汇10月30日｜伊克力西斯(EXEL.US)盘前涨5.78%报30.39美元。该公司第三季度调整每股收益为0.47美元，高于0.35美元的预期，销售额为53954.2万美元，超过49002万美元的预期。公司提高了2024年全年净产品收入预测。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-10-30/doc-incuipeu1079839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2475294840","title":"BUZZ--美国股票走势-Wave Life Sciences、Dominion Energy、Voyager Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2475294840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475294840?lang=zh_cn&edition=full","pubTime":"2024-10-16 23:56","pubTimestamp":1729094195,"startTime":"0","endTime":"0","summary":"    10月16日 - 尽管标准普尔 500 指数和纳斯达克指数在巨型科技股下跌的拖累下跌跌不休，但道琼斯指数在周三收复了一些失地，而银行股，特别是摩根士丹利的乐观季度收益则使大盘有所上涨。美东时间11:32，道琼斯工业平均指数  上涨0.4%，报42,924.64点，涨幅收窄。标普500指数  上涨0.16%，报5824.62点；纳斯达克综合指数  上涨0.02%，报18319.536点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e0d2f042c4e70b32b31caa57119ceaee","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMO","NVDA","SDOW","NVAX","COIN","WVE","D","AMPS","IBKR","DDM","GNRC","ULTA","AEP","DJX","QLD",".SPX","ADSK","ATO",".DJI","SQQQ","ABT","SCLX","QID","SBUX","AVTR","ASPN","LENZ","PSQ","APLD",".IXIC","NVCR","SYF","ASML","LRN","JBHT","UDOW","IBM","CSCO","DXD","CNP","DOG","WAT","EXEL","YUM","MNQmain","VYGR","NQmain","PLD"],"gpt_icon":1},{"id":"2475780994","title":"BUZZ--美国股票走势-美国联合航空公司、摩根士丹利、欧特克公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2475780994","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475780994?lang=zh_cn&edition=full","pubTime":"2024-10-16 21:22","pubTimestamp":1729084934,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      10月16日 - 继前一交易日科技股和石油股下挫之后，华尔街主要股指周三开盘表现平淡，投资者正在分析摩根士丹利等银行的季度业绩。美东时间9:03，道指电子盘  上涨0.05%，报43036点。标普500指数小型股  上涨0.05%，报5,865.75点；纳斯达克100指数小型股  上涨0.11%，报20,364点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCLX","BK4560","LU1059921491.USD","WAT","IR","JBHT","IE00BVYPNW00.USD","IBM","IE00BZ9MQY76.HKD","SG9999002224.SGD","UAL","ADSK","LU0640476718.USD","CSCO","LU2326559502.SGD","SG9999002232.USD","RVTY","NVCR","AMPS","LNT","LU1861217088.USD","OMC","BK4200","PLD","NEM","LU1883839398.USD","EXEL","BK4139","YUM","SYF","LU1481011671.HKD","CNP","MS","IBKR","AEP","LU1861220207.SGD","TCS","BK4588","LU1983260115.SGD","LU0314104364.USD","ULTA","LU1992135399.USD","APLD","NVAX","ATO","AVTR"],"gpt_icon":1},{"id":"2475395961","title":"BUZZ-法院对专利纠纷案作出有利裁决后，券商上调 Exelixis 的目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2475395961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475395961?lang=zh_cn&edition=full","pubTime":"2024-10-16 19:28","pubTimestamp":1729078125,"startTime":"0","endTime":"0","summary":"    10月16日 - ** 多家券商上调癌症药物制造商Exelixis  的目标价 ** 该公司周二表示， ，美国一家地方法院在其抗癌药物卡博替尼的专利纠纷诉讼案中做出了有利于该公司的裁决，MSN Laboratories胜诉。** Guggenheim 将 EXEL 的预期收益率从 28 美元上调至 32 美元，预计该药在 2029 年的销售峰值为 22.4 亿美元至 24.9 亿美元，并称 Cabo 在 2030 年 1 月之前不会受到仿制药的冲击。** Stifel 将预期收益率从 26 美元上调至 30 美元，称 \"期待已久的 MSN 诉讼判决对 EXEL 股价构成利好\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2475986782","title":"美国研究综述-Autozone, State Street, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2475986782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475986782?lang=zh_cn&edition=full","pubTime":"2024-10-16 14:42","pubTimestamp":1729060967,"startTime":"0","endTime":"0","summary":"要闻             * Autozone Inc   ：Roth MKM恢复买入评级，目标价3634美元。* 高盛   ：巴克莱将目标价从565美元上调至588美元             * ServiceNow Inc   ：杰富瑞将目标价从900美元上调至1100美元             * State Street Corp   ：巴克莱将目标价从 103 美元上调至 108 美元             * UnitedHealth   ：Leerink Partners将目标价从620美元下调至600美元 以下是路透周三报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","EXEL","LU0130518102.USD","BK4177","OMC","IE0004445239.USD","LU0114720955.EUR","LU0868494617.USD","LU1894683264.USD","NOW","LU0345770993.USD","BK4516","STT","LU0965508806.USD","COTY","TSCO","LU0345769128.USD","LU0345769631.USD","AZO","LU1934455863.HKD","NBIX","IE0004091025.USD","PNC","LU0306807586.USD","LU0306806265.USD","IE00BZ9MQY76.HKD","AAP","JNJ","IE0034235188.USD","LU1066051225.USD","BK4592","SAGE","IE00B2B36J28.USD","LU1506573853.SGD","LU1323610961.USD","IBKR","LU0081259029.USD","LU0731783048.USD","LU2456880835.USD","IE00B1XK9C88.USD","SVCO","SCHW","PEN","IE00BFXG1179.USD","LU0162691827.USD","ORLY","UNH","KDP","LU1894683348.USD"],"gpt_icon":1},{"id":"2475638652","title":"伊克力西斯盘中异动 股价大涨5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475638652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475638652?lang=zh_cn&edition=full","pubTime":"2024-10-15 23:00","pubTimestamp":1729004427,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日23时00分，伊克力西斯股票出现异动，股价大幅上涨5.87%。截至发稿，该股报27.78美元/股，成交量62.3157万股，换手率0.22%，振幅5.83%。伊克力西斯股票所在的生物技术行业中，整体跌幅为0.56%。伊克力西斯公司简介：Exelixis 是一家发现、开发和商业化癌症治疗的生物制药公司， 其先导分子 cabozantinib 以 Cometriq 为名用于治疗转移性甲状腺髓样癌患者，以 Cabometyx 为名用于治疗肾癌和肝癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015230027a1e0da00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241015230027a1e0da00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2468633620","title":"健康巡诊：高龄卵子可用于体外受精","url":"https://stock-news.laohu8.com/highlight/detail?id=2468633620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468633620?lang=zh_cn&edition=full","pubTime":"2024-09-20 05:01","pubTimestamp":1726779662,"startTime":"0","endTime":"0","summary":"高龄卵子可能适合体外受精随着年龄的增长，女性卵子的质量会下降，对体外受精的作用也会减弱。但一项在小鼠身上进行的研究表明，有朝一日有可能使年龄较大的卵子 \"返老还童\"，从而提高成功怀孕和产下健康婴儿的可能性。高龄卵子的新陈代谢、基因表达和能量产生都有所改善。通常建议42至45岁左右的妇女不要用自己的卵子进行体外受精，因为年龄较大的卵子出现异常的几率较高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","EXEL","BK4139"],"gpt_icon":0},{"id":"2458697316","title":"伊克力西斯2024财年第二财季实现净利润2.26亿美元，同比增加178.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458697316","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458697316?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:18","pubTimestamp":1723393080,"startTime":"0","endTime":"0","summary":"8月12日，伊克力西斯公布财报，公告显示公司2024财年第二财季净利润为2.26亿美元，同比增加178.39%；其中营业收入为6.37亿美元，同比增加35.53%，每股基本收益为0.78美元。从资产负债表来看，伊克力西斯总负债6.53亿美元，其中短期债务0.00美元，资产负债比为4.25，流动比率为4.27。机构评级：截至2024年8月12日，当前有19家机构对伊克力西斯目标价做出预测，其中目标均价为27.21美元，其中最低目标价为18.00美元，最高目标价为33.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200180295904710&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081200180295904710&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"2457849746","title":"伊克力西斯盘中异动 早盘股价大涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457849746","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457849746?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:32","pubTimestamp":1723037522,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时32分，伊克力西斯股票出现异动，股价快速拉升5.65%。截至发稿，该股报24.78美元/股，成交量16.1416万股，换手率0.06%，振幅3.16%。伊克力西斯股票所在的生物技术行业中，整体跌幅为0.59%。伊克力西斯公司简介：Exelixis 是一家发现、开发和商业化癌症治疗的生物制药公司， 其先导分子 cabozantinib 以 Cometriq 为名用于治疗转移性甲状腺髓样癌患者，以 Cabometyx 为名用于治疗肾癌和肝癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408072132029f177477&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408072132029f177477&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"2457004543","title":"伊克力西斯预计全年总营收为19.75亿美元至20.75亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457004543","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457004543?lang=zh_cn&edition=full","pubTime":"2024-08-07 04:48","pubTimestamp":1722977289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2456529964","title":"Exelixis Inc    预计每股收益 30 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2456529964","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456529964?lang=zh_cn&edition=full","pubTime":"2024-08-03 10:03","pubTimestamp":1722650595,"startTime":"0","endTime":"0","summary":"   * Exelixis公司   将于8月6日公布截至2024年6月30日的财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，18位分析师的平均预期显示，这家总部位于加利福尼亚州阿拉米达的公司的营收将从去年同期的4.6985亿美元降至4.65005亿美元，降幅为1.0%。* LSEG 分析师对 Exelixis Inc 的平均预期为每股收益 30 美分。* 华尔街对 Exelixis Inc 的 12 个月目标价中位数为 27.00 美元，高于其 24.17 美元的最新收盘价。8月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Exelixis Inc    预计每股收益 30 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2455431968","title":"奥本海默：维持Exelixis(EXEL.US)评级，由优于大市调整至优于大市评级, 目标价由29.00美元调整至29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455431968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455431968?lang=zh_cn&edition=full","pubTime":"2024-07-31 00:48","pubTimestamp":1722358082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exelixis.com","stockEarnings":[{"period":"1week","weight":-0.0026},{"period":"1month","weight":-0.0374},{"period":"3month","weight":0.2731},{"period":"6month","weight":0.5357},{"period":"1year","weight":0.4297},{"period":"ytd","weight":0.0192}],"compareEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":-0.0319},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0541},{"period":"1year","weight":0.2471},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Exelixis, Inc.是一家生物科技公司，致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司，并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ（卡博替尼胶囊，公司全资的多靶点受体酪氨酸激酶抑制剂）。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品，认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.56,"avgChangeRate":0.018733},{"month":2,"riseRate":0.458333,"avgChangeRate":0.015199},{"month":3,"riseRate":0.541667,"avgChangeRate":-0.009275},{"month":4,"riseRate":0.541667,"avgChangeRate":0.053269},{"month":5,"riseRate":0.44,"avgChangeRate":-0.000424},{"month":6,"riseRate":0.56,"avgChangeRate":0.026357},{"month":7,"riseRate":0.56,"avgChangeRate":0.051069},{"month":8,"riseRate":0.44,"avgChangeRate":-0.011108},{"month":9,"riseRate":0.44,"avgChangeRate":-0.043067},{"month":10,"riseRate":0.56,"avgChangeRate":-0.003645},{"month":11,"riseRate":0.6,"avgChangeRate":0.059719},{"month":12,"riseRate":0.64,"avgChangeRate":0.054171}],"exchange":"NASDAQ","name":"伊克力西斯","nameEN":"Exelixis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伊克力西斯,EXEL,伊克力西斯股票,伊克力西斯股票老虎,伊克力西斯股票老虎国际,伊克力西斯行情,伊克力西斯股票行情,伊克力西斯股价,伊克力西斯股市,伊克力西斯股票价格,伊克力西斯股票交易,伊克力西斯股票购买,伊克力西斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}